Outlook Aims To Reverse US FDA’s Rejection Of Bevacizumab For AMD

Low On Cash, Rush Is On To Clarify Agency’s Concerns

Outlook Therapeutics received a complete response letter citing manufacturing issues and seeking more data for Lytenava (ONS-5010), its bevacizumab injection for wet age-related macular degeneration.

Close up cropped shot, face of senior woman eye looking straight, into distance. — Outlook will request at Type A meeting with the FDA to discuss the CRL • Source: Shutterstock

Outlook Therapeutics, Inc. planned to have its first drug approved before the end of 2023, which would have given the company a reason to raise fresh capital. Instead, Outlook revealed on 30 August that the US Food and Drug Administration issued a complete response letter (CRL) rejecting Lytenava (ONS-5010), a proprietary formulation of bevacizumab, for the treatment of wet age-related macular degeneration (AMD).

Iselin, NJ-based Outlook said the FDA acknowledged ONS-5010’s efficacy in the pivotal Phase III NORSE TWO clinical trial, but indicated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

20 Jun 2025

• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

16 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

13 Jun 2025

• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.